

PERSONAL INFORMATION

Marco Iannetta



📍 Tor Vergata University
Department of Systems Medicine
Via Montpellier 1, 00133 Rome (Italy)

☎ +39 0620903220 📠 +39 3929986115

✉ marco.iannetta@uniroma2.it; marco.iannetta@ptvonline.it

Male | 19/05/1980 | Italian

PROFESSIONAL PROFILE and RESEARCH ACTIVITIES

07/11/2022 to present

Associate Professor

Tor Vergata University, Department of Systems Medicine
Via Montpellier 1, 00133 Rome (Italy)

- Pathogenesis of infectious diseases in immunocompromised hosts
- Viral infections
- Host-pathogen interaction

Infectious and Tropical Diseases (SC 06/D4, SSD MED17)

28/10/2022 to present

Elected Member of the Steering Committee of SIMIT Lazio

Società Italiana di Malattie Infettive (SIMIT)

Lazio Regional Office

06/09/2022 to present

Elected Member of the Faculty Board of Medicine and Surgery

Tor Vergata University of Rome

School of Medicine

07/11/2019 to 06/11/2022

Research Associate (RTDB)

Tor Vergata University, Department of Systems Medicine
Via Montpellier 1, 00133 Rome (Italy)

- Pathogenesis of infectious diseases in immunocompromised hosts
- Viral infections
- Host-pathogen interaction

Infectious and Tropical Diseases (SC 06/D4, SSD MED17)

01/11/2021 to present

PhD course MIMIT (Microbiologia, Immunologia, Malattie Infettive, Trapianti)

Tor Vergata University of Rome
Member of the PhD MIMIT Board

Infectious and Tropical Diseases (SC 06/D4, SSD MED17)

01/12/2015 to 31/03/2016

Post-doctoral Research Fellow

Sapienza, University of Rome, Department of Public Health and Infectious Diseases
Piazzale Aldo Moro 5, 00185 Rome (Italy)

- Eradication strategies for HIV-1 infection with the association of highly active antiretroviral therapies and interferon

Infectious and Tropical Diseases

01/12/2012 to 30/10/2015

Post-doctoral Research Fellow

INSERM Unit 1016, Department of Infection, Immunity and Inflammation,
Dendritic Cell Physiology Team
Institut Cochin, Bat. G. Roussy, 27 Rue Fg. St. Jacques, 75014 Paris (France)

- Investigating the role of dendritic cells and their modification in HIV-1 and HIV-2 infection
- Investigating the role of type I, II and III interferons in the immune pathogenesis of HIV-1 and HIV-2

infection

- Investigating the immune response to Chlamydia muridarum in a mouse model in order to develop a vaccination strategy

Immunology of Infectious Diseases

CLINICAL EXPERIENCE

01/01/2020 to present

Infectious Disease Specialist

POLICLINICO TOR VERGATA
Viale Oxford 81, 00133 Rome, Italy

- Management of inpatients with infectious and tropical diseases
- Sars-CoV-2 hospitalized patients
- Immunocompromised patients with opportunistic infections

Infectious and Tropical Diseases

01/04/2016 to 30/10/2019

Infectious Disease Specialist

National Institute of Infectious Diseases (INMI) Lazzaro Spallanzani
Via Portuense 292, 00149 Rome (Italy)

- Pathogenesis of infectious diseases in immunocompromised hosts
- Emerging Infectious Diseases
- Arboviral Infections

Infectious and Tropical Diseases

2011-2012

Infectious Disease Consultant

Istituto Neurologico Mediterraneo Neuromed, IRCCS Via Atinense, 18, 86077 Pozzilli (IS) (Italy)
Istituto Clinico Riabilitativo Villa delle Querce Via delle Vigne, 19, 00040 Nemi (RM) (Italy)

- Management of hospital acquired infections

Infectious and Tropical Diseases

EDUCATION AND TRAINING

2018

National Scientific Habilitation (ASN): Associate Professor of Infectious Diseases (06/D4 MED17)

ASN MIUR (Italy)

- Infectious Diseases (06/D4 MED17)

2018

Advanced Training in Anti-infective Therapy (SITA Campus)

Società Italiana Terapia Antinfettiva (SITA) (Italy)

- Anti-infective therapy

2016

National Qualification as “Flow Cytometry Expert in Immunology”

Società Italiana di Citometria-GIC, Rome (Italy)

- Flow cytometry protocols and application to immunology and infectious diseases

2016

Mini Course on Ultrasound in Tropical Medicine

University of Pavia, Dipartimento di Scienze Clinico Chirurgiche, Diagnostiche e Pediatriche (Italy)

- Ultrasound in the setting of tropical medicine

2013

Statistics in Medicine

Stanford Online, OpenEdX (free online offering), Stanford (California)

- Statistic methods for medical sciences

2013

Small Animal Model Training Course

CNRS Formation Entreprises (France)

- Training for small animal model experimental studies

- 2009 - 2012 **PhD in Infectious Diseases and Immunological Therapy**
Sapienza University of Rome, Rome (Italy)
- HIV-1 Infection: pathogenesis
 - JCV infection in the immunocompromised host
- 2010 - 2011 **Advanced Training in “Clinical Management of Antiviral Drug Resistances”**
Tor Vergata University (Italy)
- Antiviral drug management in the setting of HIV, HBV, HCV, Herpetic infections
- 2011 **Advanced Training in “Ultrasonography”**
SIUMB (Società Italiana di Ultrasonologia in Medicina e Biologia), Rome (Italy)
- Ultrasonography in medicine
- 2011 **Second Level Master “Sepsis in Surgery”**
Catholic University of Rome “Sacro Cuore” (Italy)
- Management of infectious complications after surgery
- 2005-2009 **Residency in Infectious Diseases**
Sapienza University (Italy)
- Infectious and Tropical Diseases
- 2005 **MD Degree**
Sapienza University, School of Medicine (Italy)
- Medical degree

AWARDS AND EDITORIAL ACTIVITIES

- Awards**
- July 2015**
Post-doctoral Research Fellowship; INSERM
(Institut National de la Santé et de la Recherche Médicale), Paris, France
- June 2013**
Post-doctoral Research Fellowship
DIM-Malinf (Domaine d'Intérêt Majeur Maladie Infectieuses), Paris, France
- December 2012**
Post-doctoral Research Fellowship For Young Investigators
SIMIT (Società Italiana di Malattie Infettive e Tropicali), Florence, Italy
- Grants**
- October 2021**
Gilead Italia (Milano, IT)
Project: “Networking territoriale tra i Servizi per le Dipendenze e l’ambulatorio di malattie infettive per la cura dell’HCV del Policlinico Tor Vergata di Roma attraverso una piattaforma online per facilitare il Linkage to Care e migliorare il percorso di cura della popolazione chiave dei consumatori di sostanze”
- Editorial activity**
- 2022 Guest Associate Editor for a special issue titled “Post-translational modifications and anti-virus immune response” in *Frontiers in Immunology* (viral immunology section)
- 2022 Guest Editor for a special issue on *MDPI Life*, titled “Targeting the Gut during Infections: From Bench to Bedside”
- 2022 Review editor in the editorial board of *Frontiers in Microbiology*
- 2021 Lead Guest Editor for a special issue on *MDPI Life*, titled “Immunology of Infectious diseases”

TEACHING ACTIVITIES

- 2018 To present **Teaching and tutoring activities**
Tor Vergata University of Rome
PhD course MIMIT (Microbiologia, Immunologia, Malattie Infettive, Trapianti)
- 2018 To present **Infectious and tropical Diseases**
Tor Vergata University of Rome
Systemic Pathology III
International Medical School
- 2018 To present **Teaching and tutoring activities**
Tor Vergata University of Rome
Internship in Infectious Diseases

ADDITIONAL INFORMATION

Publications and metrics 81 papers in peer-reviewed journals
1299 total citations
H index: 19

List of publications

- Mastrosora I, Gagliardini R, Segala FV, Mondì A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, **Iannetta M**, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastrì E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; ESCAPE study group. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study). *EClinicalMedicine*. 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895.
- Ricci D, Etna MP, Severa M, Fiore S, Rizzo F, **Iannetta M**, Andreoni M, Balducci S, Stefanelli P, Palamara AT, Coccia EM. Novel evidence of Thymosin $\alpha 1$ immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model. *Int Immunopharmacol*. 2023 Mar 13;117:109996. doi:10.1016/j.intimp.2023.109996.
- Rossi B, Barreca F, Benvenuto D, Braccialarghe N, Campogiani L, Lodi A, Aguglia C, Cavasio RA, Giacalone ML, Kontogiannis D, Moccione M, Malagnino V, Andreoni M, Sarmati L, **Iannetta M**. Human Arboviral Infections in Italy: Past, Current, and Future Challenges. *Viruses*. 2023 Jan 27;15(2):368. doi:10.3390/v15020368.
- Campogiani L, **Iannetta M**, Di Lorenzo A, Zordan M, Pace PG, Coppola L, Compagno M, Malagnino V, Teti E, Andreoni M, Sarmati L. Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience. *Microorganisms*. 2023 Jan 25;11(2):312. doi: 10.3390/microorganisms11020312.
- Infante M, Pieri M, Lupisella S, Mohamad A, Bernardini S, Della-Morte D, Fabbri A, De Stefano A, **Iannetta M**, Ansaldo L, Crea A, Andreoni M, Morello M. Admission eGFR predicts in-hospital mortality independently of admission glycemia and C-peptide in patients with type 2 diabetes mellitus and COVID-19. *Curr Med Res Opin*. 2023 Feb 7:1-31. doi: 10.1080/03007995.2023.2177380.
- Malagnino V, Salpini R, Teti E, Compagno M, Ferrari L, Mulas T, Svicher V, Zordan M, Basso M, Battagin G, Panese S, Rossi MC, Scaggiante R, Zago D, **Iannetta M**, Parisi SG, Andreoni M, Sarmati L. Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort. *Viruses*. 2023 Jan 10;15(1):193. doi: 10.3390/v15010193
- Basso M, Pirola N, Pascoli S, Bragato B, Vinci A, **Iannetta M**, Colombo F, Geremia N, Martignago L, Rossi MC, Cipriani L, Giobbia M, Scotton PG, Parisi SG. Humoral Response after Two Doses of BNT162b2 mRNA Vaccine Has a Role in Predicting Response after Three Doses That Is Related to Plasma HIV Viremia and Nadir CD4+ Cell Count in HIV-Positive Patients. *Vaccines (Basel)*. 2022 Dec 30;11(1):82. doi: 10.3390/vaccines11010082
- Lai A, Bergna A, Della Ventura C, Menzo S, Bruzzone B, Sagradi F, Ceccherini-Silberstein F, Weisz A, Clementi N, Brindicci G, Vicenti I, Sasset L, Caucchi S, Corvaro B, Ippoliti S, Acciarri C, De Pace V, Lanfranchi L, Bellocchi MC, Giurato G, Ferrarese R, Lagioia A, Francisci D, Colombo ML, Lazzarin S, Ogliastro M, Cappelletti MR, **Iannetta M**, Rizzo F, Torti C, Fumi M, d'Avenia M, Brusa S, Greco F, Menchise A, Letizia V, Vaccaro E, Santoro CR, Fracalvieri C, Testa S, Carioti L, Rocco T, Saracino A, Cattelan A, Clementi M, Sarmati L, Riva A, Galli M, Antinori S, Zehender G, Sars-CoV-Italian Research Enterprise-Scire Collaborative Group. Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April-December 2021 in Italy. *Viruses*. 2022 Nov 12;14(11):2508. doi: 10.3390/v14112508.
- Barchi V, Rindi LV, Iannazzo R, Massa B, De Simone G, Andreoni M, Sarmati L, **Iannetta M**. Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient. *AIDS*. 2022 Dec 1;36(15):2231-2233. doi: 10.1097/QAD.0000000000003370
- Di Lorenzo A, Tedde S, Pace PG, Campogiani L, Ansaldo L, Lodi A, Zordan M, Barreca F, Caldara F, Rossi B, Imeneo A, Alessio G, Crea AMA, Checchi D, Malagnino V, Teti E, Coppola L, Palmieri R, Buccisano F, Andreoni M, Sarmati L, **Iannetta M**. Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients. *Biomedicines*. 2022 Nov 2;10(11):2788. doi: 10.3390/biomedicines10112788.

11. Alessio G, Imeneo A, Di Lorenzo A, Rossi B, Sorace C, Compagno M, Coppola L, Campogiani L, Crea AMA, Malagnino V, Buccisano F, Andreoni M, Sarmati L, **Iannetta M**. Longitudinal Evaluation of the QuantiFERON-TB Gold Plus Assay in Hospitalized COVID-19 Patients with a First Indeterminate Result: Resolution of Inflammation and Restoration of T-Lymphocyte Counts and Interferon-Gamma Production. *Microbiol Spectr*. 2022 Sep 13:e0185822
12. **Iannetta M**, Crea AMA, Di Lorenzo A, Campogiani L, Teti E, Malagnino V, Compagno M, Coppola L, Piermatteo L, Palmieri G, Cimino C, Salpini R, Zingaropoli MA, Ciardi MR, Mastroianni CM, Parisi SG, Svicher V, Andreoni M, Sarmati L. Hepatitis B-Related Hepatic Flare During Immune Reconstitution Syndrome After Antiretroviral Treatment Initiation in an HBV Surface Antigen-Positive Patient With HIV: Viroimmunological and Histological Characterization. *Open Forum Infect Dis*. 2022 Aug 29;9(9):ofac451.
13. Compagno M, Navarra A, Campogiani L, Coppola L, Rossi B, **Iannetta M**, Malagnino V, Parisi SG, Mariotti B, Cerretti R, Arcese W, Goletti D, Andreoni M, Sarmati L. Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, Rome. *Int J Environ Res Public Health*. 2022 Aug 27;19(17):10693
14. Ferrari L, Compagno M, Campogiani L, Teti E, Mulas T, Checchi D, Alessio G, Caldara F, Coppola L, De Simone G, Ceccarelli L, Spalliera I, Vitale P, Grelli S, Andreoni M, Sarmati L, **Iannetta M**. Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine. *Vaccines (Basel)*. 2022 Aug 2;10(8):1238.
15. Parisi SG, Mengoli C, Basso M, Vicenti I, Gatti F, Scaggiante R, Fiaschi L, Giammarino F, **Iannetta M**, Malagnino V, Zago D, Dragoni F, Zazzi M. Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses. *Vaccines (Basel)*. 2022 Aug 2;10(8):1237.
16. Zingaropoli MA, Iannetta M, Piermatteo L, Pasculli P, Latronico T, Mazzuti L, Campogiani L, Duca L, Ferraguti G, De Michele M, Galardo G, Pugliese F, Antonelli G, Andreoni M, Sarmati L, Lichtner M, Turriziani O, Ceccherini-Silberstein F, Liuzzi GM, Mastroianni CM, Ciardi MR. Neuro-Axonal Damage and Alteration of Blood-Brain Barrier Integrity in COVID-19 Patients. *Cells*. 2022 Aug 10;11(16):2480.
17. Tarke A, Potesta M, Varchetta S, Fenoglio D, **Iannetta M**, Sarmati L, et al. Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors. *Int J Mol Sci* 2022 Jun 28;23(13):7155.
18. Zingaropoli MA, Pasculli P, **Iannetta M**, Perri V, Tartaglia M, Crisafulli SG, et al. Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. *Mult Scler J Exp Transl Clin*. 2022 Mar;8(1):20552173211065732.
19. Imeneo A, Alessio G, Di Lorenzo A, Campogiani L, Lodi A, Barreca F, ..., **Iannetta M**. In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production. *Life (Basel)*. 2022 Feb 7;12(2):244.
20. **Iannetta M**, Landi D, Cola G, Campogiani L, Malagnino V, Teti E, et al. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications. *Front Immunol*. 2021;12:796482.
21. Prezioso C, Ciotti M, Brazzini G, Piacentini F, Passerini S, Grimaldi A, ... **Iannetta M** et al. Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment. *J Clin Med*. 2022 Jan 11;11(2):347.
22. Minutolo A, Petrone V, Fanelli M, **Iannetta M**, Giudice M, Ait Belkacem I, et al. High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients. *Pathogens*. 2021 Dec 18;10(12):1639.
23. Tomassetti F, Nuccetelli M, Sarubbi S, Gisone F, Ciotti M, Spinazzola F, ... **Iannetta M** et al. Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection. *Int Immunopharmacol*. 2021 Oct;99:108013.
24. **Iannetta M**, Landi D, Cola G, Malagnino V, Teti E, Fraboni D, et al. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers. *Mult Scler Relat Disord*. 2021 Oct;55:103157.
25. Severa M, Diotti RA, Etna MP, Rizzo F, Fiore S, Ricci D, ... **Iannetta M** et al. Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. *PLoS Pathog*. 2021 Sep;17(9):e1009878.
26. Isnard S, Hatton EX, **Iannetta M**, Guillerme J-B, Hosmalin A. Cell-Associated HIV Cross-Presentation by Plasmacytoid Dendritic Cells Is Potentiated by Noncognate CD8+ T Cell Preactivation. *J Immunol*. 2021 Jul 1;207(1):15–22.
27. **Iannetta M**, Buccisano F, Fraboni D, Malagnino V, Campogiani L, Teti E, et al. Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study. *Sci Rep*. 2021 Jun 17;11(1):12762.
28. Balestrieri E, Minutolo A, Petrone V, Fanelli M, **Iannetta M**, Malagnino V, et al. Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients. *EBioMedicine*. 2021 Apr;66:103341.
29. Infante M, Buoso A, Pieri M, Lupisella S, Nuccetelli M, Bernardini S, ... **Iannetta M** et al. Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study. *J Am Coll Nutr*. 2021 Feb 18;1–16.
30. Malagnino V, Cerva C, Teti E, Campogiani L, Compagno M, Foroghi Biland L, ... **Iannetta M** et al. Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers. *Sci Rep*. 2021 Feb 17;11(1):3965.
31. Malagnino V, Teti E, Compagno M, Coppola L, Salpini R, Svicher V, ... **Iannetta M** et al. HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort. *Microorganisms*. 2021 Feb 15;9(2):396.
32. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, **Iannetta M**, et al. Depressive and anxiety symptoms in patients with SARS-CoV2 infection. *J Affect Disord*. 2021 Jan 1;278:339–40.
33. Zingaropoli MA, Nijhawan P, Carraro A, Pasculli P, Zuccalà P, Perri V, ... **Iannetta M** et al. Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia. *Front Immunol*. 2021;12:627548.

34. Scutari R, Piermatteo L, Ciancio Manuelli M, **Iannetta M**, Salpini R, Bertoli A, et al. Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. *Life (Basel)*. 2020 Nov 23;10(11):E302.
35. Salpini R, Malagnino V, Piermatteo L, Mulas T, Alkhatib M, Scutari R, ... **Iannetta M** et al. Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. *Microorganisms*. 2020 Nov 18;8(11):E1819.
36. **Iannetta M**, Cesta N, Stingone C, Malagnino V, Teti E, Vitale P, et al. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. *Mult Scler Relat Disord*. 2020 Oct;45:102442.
37. Vairo F, Aimè Coussoud-Mavoungou MP, Ntoumi F, Castilletti C, Kitembo L, Haider N, ... **Iannetta M** et al. Chikungunya Outbreak in the Republic of the Congo, 2019–Epidemiological, Virological and Entomological Findings of a South-North Multidisciplinary Taskforce Investigation. *Viruses*. 2020 Sep 13;12(9):E1020.
38. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, **Iannetta M**, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. *Brain Behav Immun*. 2020 Aug;88:11–6.
39. Prezioso C, Zingaropoli MA, **Iannetta M**, Rodio DM, Altieri M, Conte A, et al. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis? *Mult Scler Relat Disord*. 2020 Jun;41:102008.
40. Ciardi MR, Zingaropoli MA, **Iannetta M**, Prezioso C, Perri V, Pasculli P, et al. JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis. *Virology*. 2020 Feb 11;17(1):23.
41. Vita S, Zuccalà P, Savinelli S, Mascia C, Rossi R, Schiavone F, ... **Iannetta M** et al. Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection. *J Immunol Res*. 2020;2020:2781350.
42. **Iannetta M**, Isnard S, Manuzak J, Guillaume J-B, Notin M, Bailly K, et al. Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection. *Front Immunol*. 2020;11:1658.
43. **Iannetta M**, Di Caro A, Nicastrì E, Vairo F, Masanja H, Kobinger G, et al. Viral Hemorrhagic Fevers Other than Ebola and Lassa. *Infect Dis Clin North Am*. 2019 Dec;33(4):977–1002.
44. Nicastrì E, Vairo F, Mencarini P, Battisti A, Agrati C, Cimini E, ... **Iannetta M** et al. Unexpected human cases of cutaneous anthrax in Latium region, Italy, August 2017: integrated human-animal investigation of epidemiological, clinical, microbiological and ecological factors. *Euro Surveill*. 2019 Jun;24(24).
45. **Iannetta M**, Savinelli S, Rossi R, Mascia C, Marocco R, Vita S, et al. Myeloid and lymphoid activation markers in AIDS and non-AIDS presenters. *Immunobiology*. 2019 Mar;224(2):231–41.
46. **Iannetta M**, Zingaropoli MA, Latronico T, Pati I, Pontecorvo S, Prezioso C, et al. Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients. *Sci Rep*. 2019 Jan 22;9(1):311.
47. Ciardi MR, **Iannetta M**, Zingaropoli MA, Salpini R, Aragri M, Annecca R, et al. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. *Open Forum Infect Dis*. 2019 Jan;6(1):ofy356.
48. D'Abramo A, Lepore L, **Iannetta M**, Gebremeskel Tekle S, Corpolongo A, Scorzoloni L, et al. Imported severe malaria and risk factors for intensive care: A single-centre retrospective analysis. *PLoS One*. 2019;14(11):e0225135.
49. Cella E, Foley BT, Riva E, Scolamacchia V, Ceccarelli G, Vita S, ... **Iannetta M** et al. HIV-2 Infection in a Migrant from Gambia: The History of the Disease Combined with Phylogenetic Analysis Revealed the Real Source of Infection. *AIDS Res Hum Retroviruses*. 2018 Dec;34(12):1090–4.
50. Gebremeskel Tekle S, Corpolongo A, D'Abramo A, Giancola ML, **Iannetta M**, Scorzoloni L, et al. Case Report: Delayed Diagnosis of Congenital Malaria by *Plasmodium vivax* in a Newborn of an Eritrean Woman with Varicella Infection. *Am J Trop Med Hyg*. 2018 Sep;99(3):620–2.
51. Lalle E, Colavita F, **Iannetta M**, Gebremeskel Tekle S, Carletti F, Scorzoloni L, et al. Prolonged detection of dengue virus RNA in the semen of a man returning from Thailand to Italy, January 2018. *Euro Surveill*. 2018 May;23(18).
52. D'Abramo A, Gebremeskel Tekle S, **Iannetta M**, Scorzoloni L, Oliva A, Paglia MG, et al. Severe *Plasmodium ovale* malaria complicated by acute respiratory distress syndrome in a young Caucasian man. *Malar J*. 2018 Apr 2;17(1):139.
53. Biava M, Caglioti C, Castilletti C, Bordi L, Carletti F, Colavita F, ... **Iannetta M** et al. Persistence of ZIKV-RNA in the cellular fraction of semen is accompanied by a surrogate-marker of viral replication. Diagnostic implications for sexual transmission. *New Microbiol*. 2018 Jan;41(1):30–3.
54. Zingaropoli MA, **Iannetta M**, Pontecorvo S, Anzivino E, Prezioso C, Rodio DM, et al. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus. *Biomed Res Int*. 2018;2018:5297980.
55. Mascia C, Pozzetto I, Kertusha B, Marocco R, Del Borgo C, Tieghi T, ... **Iannetta M** et al. Persistent high plasma levels of sCD163 and sCD14 in adult patients with measles virus infection. *PLoS One*. 2018;13(5):e0198174.
56. Colavita F, Bordoni V, Caglioti C, Biava M, Castilletti C, Bordi L, ... **Iannetta M** et al. ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC. *Mediators Inflamm*. 2018;2018:2450540.
57. Mascia C, Lichtner M, Zuccalà P, Vita S, Tieghi T, Marocco R, ... **Iannetta M** et al. Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN- γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection. *Clin Res Hepatol Gastroenterol*. 2017 Dec;41(6):644–55.
58. **Iannetta M**, Ippolito G, Nicastrì E. Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells. *Antimicrob Agents Chemother*. 2017 Sep;61(9):e01152-17.
59. **Iannetta M**, Lalle E, Musso M, Carletti F, Scorzoloni L, D'Abramo A, et al. Persistent detection of dengue virus RNA in vaginal secretion of a woman returning from Sri Lanka to Italy, April 2017. *Euro Surveill*. 2017 Aug 24;22(34).
60. Vignoli A, Rodio DM, Bellizzi A, Sobolev AP, Anzivino E, Mischitelli M, ... **Iannetta M** et al. NMR-based metabolomic approach to study urine samples of chronic inflammatory rheumatic disease patients. *Anal Bioanal Chem*. 2017 Feb;409(5):1405–13.

61. Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S, ... **Iannetta M** et al. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. *PLoS One*. 2017;12(6):e0179400.
62. Nicastri E, Castilletti C, Liuzzi G, **Iannetta M**, Capobianchi MR, Ippolito G. Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016. *Euro Surveill*. 2016 Aug 11;21(32).
63. Oliva A, Cipolla A, Gizzi F, D'Abramo A, Favaro M, De Angelis M, ... **Iannetta M** et al. Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing: A Case Report. *Medicine (Baltimore)*. 2016 Feb;95(7):e2243.
64. Anzivino E, Zingaropoli MA, **Iannetta M**, Pietropaolo VA, Oliva A, Iori F, et al. Archetype and Rearranged Non-coding Control Regions in Urothelial Bladder Carcinoma of Immunocompetent Individuals. *Cancer Genomics Proteomics*. 2016 12;13(6):499–509.
65. Oliva A, Pavone P, D'Abramo A, **Iannetta M**, Mastroianni CM, Vullo V. Role of Sonication in the Microbiological Diagnosis of Implant-Associated Infections: Beyond the Orthopedic Prosthesis. *Adv Exp Med Biol*. 2016;897:85–102.
66. Lichtner M, Rossi R, Vita S, Savinelli S, **Iannetta M**, Mascia C, et al. Blood Myeloid Dendritic Cells and slanDC in Antiretroviral Therapy- Suppressed HIV-Infected Patients. *Curr HIV Res*. 2016;14(4):331–9.
67. **Iannetta M**, Zingaropoli MA, Bellizzi A, Morreale M, Pontecorvo S, D'Abramo A, et al. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation. *PLoS One*. 2016;11(8):e0160277.
68. D'Abramo A, Zingaropoli MA, Oliva A, D'Agostino C, Al Moghazi S, De Luca G, ... **Iannetta M** et al. Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients. *PLoS One*. 2016;11(2):e0149601.
69. Pietropaolo V, Bellizzi A, Anzivino E, **Iannetta M**, Zingaropoli MA, Rodio DM, et al. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment. *J Neurovirol*. 2015 Dec;21(6):653–65.
70. Piguet V, Caucheteux SM, **Iannetta M**, Hosmalin A. Altered antigen-presenting cells during HIV-1 infection. *Curr Opin HIV AIDS*. 2014 Sep;9(5):478–84.
71. Scorzoloni L, Lichtner M, **Iannetta M**, Mengoni F, Russo G, Panni AS, et al. Sonication technique improves microbiological diagnosis in patients treated with antibiotics before surgery for prosthetic joint infections. *New Microbiol*. 2014 Jul;37(3):321–8.
72. Oliva A, D'Abramo A, D'Agostino C, **Iannetta M**, Mascellino MT, Gallinelli C, et al. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant *Klebsiella pneumoniae* bloodstream infections. *J Antimicrob Chemother*. 2014 Jun;69(6):1718–20.
73. D'Abramo A, Zingaropoli MA, Oliva A, D'Agostino C, Al Moghazi S, De Luca G, ... **Iannetta M** et al. Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis. *Mediators Inflamm*. 2014;2014:192594.
74. **Iannetta M**, Bellizzi A, Lo Menzo S, Anzivino E, D'Abramo A, Oliva A, et al. HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity. *J Neurovirol*. 2013 Jun;19(3):274–9.
75. Oliva A, Nguyen BL, Mascellino MT, D'Abramo A, **Iannetta M**, Ciccaglioni A, et al. Sonication of explanted cardiac implants improves microbial detection in cardiac device infections. *J Clin Microbiol*. 2013 Feb;51(2):496–502.
76. D'Abramo A, D'Agostino C, Oliva A, **Iannetta M**, D'Ettore G, Vullo F, et al. Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin. *ISRN AIDS*. 2013;2013:737083.
77. Russo G, **Iannetta M**, D'Abramo A, Mascellino MT, Pantosti A, Erario L, et al. *Lactococcus garvieae* endocarditis in a patient with colonic diverticulosis: first case report in Italy and review of the literature. *New Microbiol*. 2012 Oct;35(4):495–501.
78. Oliva A, Belvisi V, **Iannetta M**, Andreoni C, Mascellino MT, Lichtner M, et al. Pacemaker lead endocarditis due to multidrug-resistant *Corynebacterium striatum* detected with sonication of the device. *J Clin Microbiol*. 2010 Dec;48(12):4669–71.
79. Russo G, Lichtner M, Carnevalini M, Mascellino MT, Mengoni F, Oliva A, ... **Iannetta M** et al. Primary retroperitoneal abscesses due to *Rhodococcus equi* in a patient with severe nephrotic syndrome: successful antibiotic treatment with linezolid and tigecycline. *Int J Infect Dis*. 2010 Jun;14(6):e533-535.
80. D'Agostino C, Lichtner M, Mastroianni CM, Ceccarelli G, **Iannetta M**, Antonucci S, et al. In vivo release of alpha-defensins in plasma, neutrophils and CD8 T-lymphocytes of patients with HIV infection. *Curr HIV Res*. 2009 Nov;7(6):650–5.
81. Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, **Iannetta M**, et al. In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. *PLoS One*. 2009;4(4):e5187.

Rome, March 2023

Marco Iannetta

